Pramlintide/Insulin

普兰林肽/胰岛素

Report date: 2022/05/25 17:34:00

Base Information

Drug NamePramlintide/Insulin
Drug Alias NameA21G human insulin/Pramlintideinsulin analogue M1+普兰林肽M1PramADO-09
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionCalcitonin receptor agonistsInsulin receptor agonists
TargetsCalcitonin receptorInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyFrance
CombinationsYes Pramlintide acetateInsulin human (rDNA origin, Lilly)
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAdocia
China Registration ClassN/A

Develop Information

Active CompaniesSanofiAdocia
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A